AllianceBernstein’s Akoya BioSciences AKYA Stock Holding History

AllianceBernstein’s Portfolio AKYA Stock Details AKYA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-36,850	Closed	-$51.2K	–	3235
2025 Q1	$51.2K	Buy	36,850 +3,800	+11%	+$8.32K	﹤0.01%	3131
2024 Q4	$75.7K	Hold	33,050	–	–	﹤0.01%	3153
2024 Q3	$89.9K	Hold	33,050	–	–	﹤0.01%	3144
2024 Q2	$77.3K	Buy	33,050 +5,900	+22%	+$18.8K	﹤0.01%	3147
2024 Q1	$127K	Hold	27,150	–	–	﹤0.01%	3001
2023 Q4	$132K	Hold	27,150	–	–	﹤0.01%	3031
2023 Q3	$126K	Buy	27,150 +2,040	+8%	+$11.7K	﹤0.01%	3036
2023 Q2	$186K	Buy	25,110 +12,410	+98%	+$82.8K	﹤0.01%	2999
2023 Q1	$104K	Buy	12,700 +900	+8%	+$9.4K	﹤0.01%	3026
2022 Q4	$113K	Buy	+11,800	New	+$145K	﹤0.01%	3104
2022 Q3	–	Sell	-15,709	Closed	-$202K	–	3269
2022 Q2	$202K	Buy	+15,709	New	+$163K	﹤0.01%	3024

Other funds holding AKYA

BWLSA

Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAPAIJV

Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PCA

Peddock Capital Advisors Braintree, Massachusetts $501M AUM 29.8% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

AllianceBernstein's AKYA Position: Q2 2025 in Review

AllianceBernstein sold out of Akoya BioSciences (AKYA) in Q2 2025, closing a stake of 36,850 shares — an estimated $51.2K sold.

AllianceBernstein first reported a position in AKYA in Q2 2022 and held it in 11 quarters. The position peaked at $202K in Q2 2022. 58 funds tracked by Wall St. Rank hold AKYA as of Q2 2025.

AllianceBernstein reported no remaining Akoya BioSciences position as of Q2 2025 after selling out during the quarter.
AllianceBernstein sold 36,850 Akoya BioSciences shares in Q2 2025, an estimated $51.2K.
AllianceBernstein first reported a position in Akoya BioSciences in Q2 2022 and held it in 11 quarters.
AllianceBernstein's Akoya BioSciences position peaked at $202K in Q2 2022.
58 funds tracked by Wall St. Rank held Akoya BioSciences as of Q2 2025.

Based on AllianceBernstein's 13F filing for Q2 2025, filed 14 Aug 2025.